Literature DB >> 10488955

Haptoglobin polymorphism and peripheral arterial occlusive disease.

J Delanghe1, M Langlois, D Duprez, M De Buyzere, D Clement.   

Abstract

Haptoglobin (Hp) 2-2 phenotype is a genetic risk factor in coronary atherosclerosis. In this study, haptoglobin phenotypes were determined in 141 patients with peripheral arterial occlusive disease (PAOD) and compared to a reference population (n = 1000). The relative Hp1 allele frequency was decreased among PAOD patients (0.294 vs. 0.403 for the reference population, P < 0.01) due to an overrepresentation of the Hp 2-2 phenotype (50%, odds ratio 1.82 (95% C.I. 1.28-2.60), P < 0.001). This finding was even more pronounced in non-diabetic and in non-smoking PAOD patients (Hp1 allele frequencies: 0.265 and 0.228, respectively). Serum lipids, inflammatory parameters, and blood pressure levels were comparable among the Hp phenotypes, but serum levels of the antioxidant vitamin C were lower in Hp 2-2 patients than in patients with another phenotype (P < 0.05). In PAOD patients with severe atherosclerotic lesions, maximal walking distance of patients carrying a Hp 2-2 phenotype (225-525 m) exceeded that of other Hp phenotypes (50-242 m) (interquartile ranges) (P < 0.05). The findings demonstrate that, despite an increased risk for developing PAOD, the Hp 2-2 phenotype is associated with a longer maximal walking distance which might be attributed to the earlier reported in vitro angiogenic properties of the Hp 2-2 molecule.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488955     DOI: 10.1016/s0021-9150(99)00079-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Peripheral Arterial Disease Genetics: Progress to Date and Challenges Ahead.

Authors:  Nathan Belkin; Scott M Damrauer
Journal:  Curr Cardiol Rep       Date:  2017-11-01       Impact factor: 2.931

3.  Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin.

Authors:  Leah E Cahill; Andrew P Levy; Stephanie E Chiuve; Majken K Jensen; Hong Wang; Nawar M Shara; Shany Blum; Barbara V Howard; Jennifer K Pai; Kenneth J Mukamal; Kathryn M Rexrode; Eric B Rimm
Journal:  J Am Coll Cardiol       Date:  2013-01-09       Impact factor: 24.094

4.  Haptoglobin: A major susceptibility gene for diabetic vascular complications.

Authors:  Tal Szafranek; Stuart Marsh; Andrew P Levy
Journal:  Exp Clin Cardiol       Date:  2002

Review 5.  Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology.

Authors:  Joshua W Knowles; Themistocles L Assimes; Jun Li; Thomas Quertermous; John P Cooke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-07-26       Impact factor: 8.311

Review 6.  Human genetic variation influences vitamin C homeostasis by altering vitamin C transport and antioxidant enzyme function.

Authors:  Alexander J Michels; Tory M Hagen; Balz Frei
Journal:  Annu Rev Nutr       Date:  2013-04-29       Impact factor: 11.848

7.  Changing the face of diabetic care with haptoglobin genotype selection and vitamin e.

Authors:  Nina S Levy; Andrew P Levy
Journal:  Rambam Maimonides Med J       Date:  2011-04-30

8.  Haptoglobin genotype and risk markers of cardiovascular disease in patients with chronic kidney disease.

Authors:  Charlotte Strandhave; My Svensson; Henrik Krarup; Jeppe Hagstrup Christensen
Journal:  Int J Nephrol       Date:  2013-03-16

9.  New circulating biomarkers for predicting cardiovascular death in healthy population.

Authors:  Olle Melander; Javier Modrego; Jose J Zamorano-León; Juana M Santos-Sancho; Vicente Lahera; Antonio J López-Farré
Journal:  J Cell Mol Med       Date:  2015-08-10       Impact factor: 5.310

10.  Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study.

Authors:  Trevor J Orchard; Wanjie Sun; Patricia A Cleary; Saul M Genuth; John M Lachin; Paula McGee; Andrew D Paterson; Philip Raskin; Yefim Anbinder; Andrew P Levy
Journal:  Diabetes       Date:  2013-06-12       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.